Market news, stock analysis and investing ideas

Biotech ETF XBI Gains 2.57% After Thursday's 6.73% Drop; Large Stocks Barely Move

XBI recovered part of Thursday's 6.73% slide on Friday, rising 2.57% on above-average volume. Five large biotech stocks moved less than 2% from Thursday's close, on volume below their averages.

Biotech ETF XBI Gains 2.57% After Thursday's 6.73% Drop; Large Stocks Barely Move

State Street SPDR S&P Biotech ETF (NYSE Arca: XBI) closed at $152.21 on Friday, Nov. 6, up 2.57% from Thursday's close of $148.40. The fund rose in both the pre-market and the regular session. No company release or filing among the available news explains the move.

A rebound the large biotech stocks did not share

XBI recovered part of a 6.73% one-day loss, but the large stocks in the sector moved far less. Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Biogen each finished within 2% of Thursday's close. It is not clear which stocks lifted the fund.

How the fund and the large stocks traded

XBI rose 1.03% in pre-market trading (the session before the 9:30 a.m. ET open). It then rose further in the regular session. The fund opened 0.28% above Thursday's close and traded between $147.56 and $152.92.

About 10.10 million shares changed hands, against a 10-day average of 8.92 million, or 1.19 times normal volume.

Four of the five large stocks fell in pre-market trading, from 1.33% for Regeneron to 2.65% for Amgen. Biogen edged up 0.21%. All five then rose in the regular session, by 2.09% (Gilead) to 3.18% (Vertex), measured from their pre-market closes. Against Thursday's close, the day moves were small:

  • Biogen: $248.35, up 1.81%
  • Vertex: $547.09, up 0.85%
  • Regeneron: $904.35, up 0.16%
  • Amgen: $460.42, up 0.03%
  • Gilead: $166.89, down 0.41%

Volume in all five ran below its 10-day average, from 0.53 times normal for Gilead to 0.71 times for Amgen.

Since Oct. 8, XBI had slipped 0.60% through Thursday. It peaked at $160.29 on Oct. 29, then rose 1.92% on Nov. 3 and 2.67% on Nov. 4, to $159.10, before Thursday's drop.

No clear catalyst in the news flow

Nothing in the available news accounts for Thursday's drop or Friday's bounce. Gilead announced data at 12:20 p.m. ET Friday from its PURPOSE 5 study, which showed higher persistence among patients starting twice-yearly lenacapavir for HIV prevention. The stock closed down 0.41% from Thursday.

The analyst items are small. Leerink Partners kept a Market Perform rating on Amgen and raised its price target to $464 on Thursday after the close. Freedom Broker downgraded Amgen to Hold and raised its target to $470 at 6:53 p.m. ET Friday, after the session ended. Needham kept a Buy rating on Vertex and raised its target on Thursday evening.

Two Regeneron insider sales were also reported. Director Huda Y. Zoghbi sold 7,439 shares worth over $7.2 million, and another insider sold about $3.83 million of stock. Regeneron closed up 0.16% on Friday.

Large companies, small effect on the day

The large stocks are big companies: Amgen has a market value of about $249.05 billion, Gilead about $207.00 billion and Vertex about $138.71 billion. Their moves of 0.41% or less in either direction (Biogen and Vertex aside) came on a day the fund rose 2.57%, so the day's gain in the fund did not come from these stocks.

Bottom line

Friday's gain recovered part of Thursday's loss, with volume 1.19 times the fund's 10-day average and thin trading in the large stocks. No event in the available news ties the move to a specific cause.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.